Company Filing History:
Years Active: 2025
Title: The Innovations of Qi Wohltman
Introduction
Qi Wohltman is an accomplished inventor based in Belmont, California. He has made significant contributions to the field of cardiology through his innovative approaches to treating hypertrophic cardiomyopathy. His work is particularly notable for its focus on the administration of cardiac myosin inhibitors.
Latest Patents
Wohltman holds a patent for "Methods for treating hypertrophic cardiomyopathy." This patent describes methods for treating obstructive hypertrophic cardiomyopathy, which include the administration of a cardiac myosin inhibitor known as CK-3773274, also referred to as CK-274 or aficamten. The treatment methods involve titrating the daily dose based on one or more components of an echocardiogram. The daily dose may be adjusted—whether increased, maintained, decreased, or terminated—based on the results of the echocardiogram.
Career Highlights
Qi Wohltman is currently employed at Cytokinetics, Inc., where he continues to advance his research and development efforts in the field of cardiology. His innovative work has the potential to significantly improve treatment options for patients suffering from hypertrophic cardiomyopathy.
Collaborations
Wohltman collaborates with notable colleagues, including Fady Malik and Stuart Kupfer, who contribute to the research and development efforts at Cytokinetics, Inc. Their combined expertise enhances the potential for groundbreaking advancements in cardiac treatment.
Conclusion
In summary, Qi Wohltman is a pioneering inventor whose work in treating hypertrophic cardiomyopathy showcases the importance of innovation in medicine. His contributions are paving the way for improved patient outcomes in cardiology.